<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560829</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.294</org_study_id>
    <secondary_id>2020-A02325-34</secondary_id>
    <nct_id>NCT04560829</nct_id>
  </id_info>
  <brief_title>Additive Value of Physiology Coronary in Clinical Practice</brief_title>
  <acronym>PRINCIPE</acronym>
  <official_title>Additive Value of Physiology Coronary in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The important evidence of coronary microcirculation for the management of patients with&#xD;
      coronary artery disease is only increasing. Thus, in recent years, a number of studies have&#xD;
      shown that the demonstration of coronary microvascular disease (CMVD) contributes to&#xD;
      cardiovascular morbidity and mortality increases independently of epicardial damage. This has&#xD;
      been shown in stable coronary artery disease with screening for CMVD when there is no&#xD;
      significant epicardial involvement and allowing the implementation of an adapted treatment&#xD;
      then reducing the symptoms and improving the quality of life of our patients. (1). The&#xD;
      prognostic nature of CMVD has also been identified in stable disease after coronary&#xD;
      angioplasty (2) but also in patients with infarcts reperfused by coronary angioplasty (3).&#xD;
&#xD;
      The complete exploration of the epicardial and microvascular coronary vascularization is&#xD;
      grouped under the name of the subspecialty: coronary physiology. Thus, an internationally&#xD;
      recognized algorithm for exploring coronary physiology has been published (4).&#xD;
&#xD;
      However, this algorithm is still little followed. The PRINCIPE registry aims to assess the&#xD;
      prevalence of CMVD with the use of a standardized algorithm for exploring coronary physiology&#xD;
      by coronary angiography in our center in current practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Rate of CMVD defined by microcirculatory resistance index (IMR) &gt; 25</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of macro and microvascular angina</measure>
    <time_frame>At inclusion</time_frame>
    <description>Macro and microvascular angina rate according to international angiographic diagnostic criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>Coronary angiography and coronary physiology parameters:% of epicardial stenosis, FFR, CFR, IMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>SPEC parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>Cardiac echography parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>Stress cardiac echography parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>MRI parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between coronary physiology parameters and imaging data</measure>
    <time_frame>At inclusion</time_frame>
    <description>Cardiac CT parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the symptoms of angina pectoris</measure>
    <time_frame>12 months</time_frame>
    <description>Brief angina questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate of peri-procedural myocardial distress</measure>
    <time_frame>At inclusion</time_frame>
    <description>Post PCI troponin rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate medical consumption</measure>
    <time_frame>12 months</time_frame>
    <description>Number of medical consultation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serious cardiovascular event rate</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular event</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Microvascular Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient undergoing coronary artery assessment. Patients will be included in the study&#xD;
        prospectively during the assessment with collection of the patient's non-objection during&#xD;
        follow-ups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients over 18 years of age&#xD;
&#xD;
          -  Having a coronary angiography&#xD;
&#xD;
          -  Presenting in pain or having performed a positive ischemia test&#xD;
&#xD;
          -  Affiliated with social security&#xD;
&#xD;
          -  Non-opposition to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adult patient protected by law (article L1121-8)&#xD;
&#xD;
          -  Person deprived of liberty (article L1121-8)&#xD;
&#xD;
          -  Pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Gilles Barone Rochette, MD PhD</last_name>
    <phone>+33476768888</phone>
    <email>gbarone@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clemence Charlon, MSc</last_name>
    <phone>+33476766652</phone>
    <email>ccharlon@chu-grenoble.fr</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

